Shareholders of Hillenbrand would probably like to forget the past six months even happened. The stock dropped 22.8% and now trades at $20.96. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Enviri’s stock price has taken a beating over the past six months, shedding 36.6% of its value and falling to $6.59 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Although the S&P 500 is down 6.9% over the past six months, Trex’s stock price has fallen further to $54.94, losing shareholders 15.8% of their capital. This might have investors contemplating their next move.
Dentsply Sirona’s stock price has taken a beating over the past six months, shedding 46.9% of its value and falling to $12.92 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Over the last six months, Avnet shares have sunk to $45.83, producing a disappointing 16.4% loss - worse than the S&P 500’s 6.9% drop. This might have investors contemplating their next move.
What a brutal six months it’s been for Skillz. The stock has dropped 27.4% and now trades at $3.95, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
While the broader market has struggled with the S&P 500 down 6.9% since October 2024, Planet Fitness has surged ahead as its stock price has climbed by 17.2% to $97.01 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
Quest Resource’s stock price has taken a beating over the past six months, shedding 69.2% of its value and falling to $2.48 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Tyson Foods has been treading water for the past six months, recording a small return of 4.1% while holding steady at $62.30. However, the stock is beating the S&P 500’s 6.9% decline during that period.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Artivion (NYSE:AORT) and its peers.